Copyright
©The Author(s) 2021.
World J Clin Oncol. Aug 24, 2021; 12(8): 688-701
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.688
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.688
Table 1 Clinicopathological characteristics of gastric cancer patients according to the Cancer Genome Atlas classification
| Variables | EBV | MSI | CIN | GS | P value | |
| n = 30 (10.5%) | n = 58 (20.2%) | n = 179 (62.2%) | n = 20 (7%) | |||
| Age (yr) | 0.017 | |||||
| mean (± SD) | 61.4 (11.2) | 65.9 (12.5) | 60.1 (11.7) | 60.6 (12.8) | ||
| Sex | 0.101 | |||||
| Male | 23 (76.7) | 29 (50) | 103 (57.5) | 13 (65) | ||
| Female | 7 (23.3) | 29 (50) | 76 (42.5) | 7 (35) | ||
| ASA Classification | 0.753 | |||||
| I/II | 27 (90) | 50 (85.2) | 160 (89.4) | 19 (95) | ||
| III/IV | 3 (10) | 8 (13.8) | 19 (10.6) | 1 (5) | ||
| Charlson–Deyo comorbidity index | 0.011 | |||||
| < 5 | 19 (63.3) | 23 (39.7) | 112 (62.6) | 14 (70) | ||
| ≥ 5 | 11 (36.7) | 35 (60.3) | 67 (37.4) | 6 (30) | ||
| Tumor site | 0.004 | |||||
| Upper | 8 (26.7) | 6 (10.3) | 18 (10.1) | 2 (10) | ||
| Middle | 7 (23.3) | 8 (13.8) | 34 (19) | 3 (15) | ||
| Lower | 11 (36.7) | 44 (75.9) | 123 (68.7) | 13 (65) | ||
| Entire | 4 (13.3) | 0 (0) | 4 (2.2) | 2 (10) | ||
| Type of resection | < 0.001 | |||||
| Subtotal | 8 (26.7) | 45 (77.6) | 110 (61.5) | 11 (55) | ||
| Total | 22 (73.3) | 12 (22.4) | 69 (38.5) | 9 (45) | ||
| Macroscopic type | 0.244 | |||||
| I /II | 9 (34.6) | 19 (34.5) | 37 (22.7) | 4 (21.1) | ||
| III/IV | 17 (65.4) | 36 (65.5) | 126 (77.3) | 15 (78.9) | ||
| Tumor size (cm) | 0.029 | |||||
| mean (± SD) | 6.3 (4.4) | 5.3 (2.9) | 4.5 (3.0) | 5.2 (2.9) | ||
| Histological differentiation | 0.001 | |||||
| Well/moderately | 8 (26.7) | 28 (48.3) | 89 (49.7) | 2 (10) | ||
| Poorly differentiated | 22 (73.3) | 30 (51.7) | 90 (50.3) | 18 (90) | ||
| Laurén type | < 0.001 | |||||
| Intestinal | 11 (36.7) | 34 (58.6) | 88 (49.2) | 3 (15) | ||
| Diffuse/mixed | 12 (40) | 22 (37.9) | 88 (49.2) | 16 (80) | ||
| Undetermined | 7 (23.3) | 2 (3.4) | 3 (1.7) | 1 (5) | ||
| Tumor invasion | 0.277 | |||||
| pT1/pT2 | 10 (33.3) | 29 (50) | 70 (39.1) | 6 (30) | ||
| pT3/pT4 | 20 (66.7) | 29 (50) | 109 (60.9) | 15 (70) | ||
| pN status | 0.147 | |||||
| pN negative | 14 (46.7) | 32 (55.2) | 73 (40.8) | 6 (30) | ||
| pN positive | 16 (53.3) | 26 (44.8) | 106 (59.2) | 14 (70) | ||
| Lymphatic invasion | 0.156 | |||||
| Absent | 16 (53.3) | 22 (37.9) | 96 (53.6) | 8 (40) | ||
| Present | 14 (46.7) | 36 (62.1) | 83 (46.4) | 12 (60) | ||
| Venous Invasion | 0.300 | |||||
| Absent | 22 (73.3) | 35 (60.3) | 125 (69.7) | 11 (55) | ||
| Present | 8 (26.7) | 23 (39.7) | 54 (30.3) | 9 (45) | ||
| Perineural invasion | 0.267 | |||||
| Absent | 14 (46.7) | 36 (62.1) | 91 (50.8) | 8 (40) | ||
| Present | 16 (53.3) | 22 (37.9) | 88 (49.2) | 12 (60) | ||
| Peritumoral inflammatory infiltrate | < 0.001 | |||||
| Absent/mild | 8 (26.7) | 35 (60.3) | 131 (73.2) | 17 (85) | ||
| moderate/intense | 22 (73.3) | 23 (39.7) | 48 (26.8) | 3 (15) | ||
| pTNM stage | 0.014 | |||||
| I/II | 18 (60) | 40 (69) | 93 (52) | 6 (30) | ||
| III/IV | 12 (40) | 18 (31) | 86 (48) | 14 (70) | ||
Table 2 Univariate and multivariate analysis for disease-free survival and overall survival-including the Cancer Genome Atlas subgroups
| Disease-free survival | Univariate | Multivariate | ||||
| Variables | HR | 95%CI | P value | HR | 95%CI | P value |
| Male (vs female) | 0.93 | 0.59-1.46 | 0.745 | ─ | ─ | ─ |
| Age > 65 (vs < 65 yr) | 1.52 | 0.95-2.45 | 0.082 | ─ | ─ | ─ |
| Charlson < 5 (vs ≥ 5) | 0.65 | 0.40-1.05 | 0.076 | ─ | ─ | ─ |
| Total Gastrectomy (vs subtotal) | 2.33 | 1.49-3.62 | < 0.001 | 1.8 | 1.12-2.88 | 0.015 |
| Diffuse/mixed (vs others) | 1.80 | 1.15-2.83 | 0.011 | 1.24 | 0.78-1.97 | 0.367 |
| pT3/pT4 status (vs pT1/pT2) | 10.87 | 4.72-24.98 | < 0.001 | 5.64 | 2.33-13.64 | < 0.001 |
| pN+ (vs pN0) | 7.56 | 3.77-15.15 | < 0.001 | 3.25 | 1.54-6.80 | 0.002 |
| CMT (vs none) | 1.28 | 0.82-1.98 | 0.280 | ─ | ─ | ─ |
| TCGA Classification | ||||||
| GS | 1 | ─ | ─ | ─ | ─ | ─ |
| EBV | 0.42 | 0.17-1.06 | 0.068 | 0.37 | 0.14-0.94 | 0.037 |
| MSI | 0.21 | 0.09-0.52 | 0.001 | 0.31 | 0.13-0.76 | 0.010 |
| CIN | 0.43 | 0.21-0.84 | 0.014 | 0.43 | 0.22-0.87 | 0.018 |
| Overall survival | Univariate | Multivariate | ||||
| Variables | HR | 95%CI | P value | HR | 95%CI | P value |
| Male (vs female) | 1.08 | 0.72-1.63 | 0.708 | ─ | ─ | ─ |
| Age > 65 (vs < 65 yr) | 1.16 | 0.77-1.74 | 0.483 | ─ | ─ | ─ |
| Charlson < 5 (vs ≥ 5) | 1.16 | 0.84-1.88 | 0.273 | ─ | ─ | ─ |
| Total Gastrectomy (vs subtotal) | 1.90 | 1.27-2.84 | 0.002 | 1.7 | 1.11-2.60 | 0.014 |
| Diffuse/mixed (vs others) | 1.56 | 1.04-2.34 | 0.032 | 1.16 | 0.77-1.77 | 0.765 |
| pT3/pT4 status (vs pT1/pT2) | 4.50 | 2.59-7.82 | < 0.001 | 3.23 | 1.74-5.97 | < 0.001 |
| pN+ (vs pN0) | 3.29 | 2.02-5.35 | < 0.001 | 1.69 | 0.98-2.92 | 0.061 |
| CMT (vs none) | 0.96 | 0.64-1.44 | 0.841 | ─ | ─ | ─ |
| TCGA Classification | ||||||
| GS | 1 | ─ | ─ | ─ | ─ | ─ |
| EBV | 0.33 | 0.13-0.82 | 0.017 | 0.27 | 0.10-0.68 | 0.006 |
| MSI | 0.27 | 0.12-0.61 | 0.001 | 0.35 | 0.15-0.78 | 0.01 |
| CIN | 0.46 | 0.24-0.88 | 0.019 | 0.47 | 0.25-0.91 | 0.025 |
- Citation: Ramos MFKP, Pereira MA, de Mello ES, Cirqueira CDS, Zilberstein B, Alves VAF, Ribeiro-Junior U, Cecconello I. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery. World J Clin Oncol 2021; 12(8): 688-701
- URL: https://www.wjgnet.com/2218-4333/full/v12/i8/688.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i8.688